Bibliography of Scientific Papers using the Medication Event Monitoring System (MEMS®).

Maintained by AARDEX Ltd.
PUBLICATIONS BASED ON ELECTRONIC MEDICATION EVENT MONITORING

Following is a listing of 605 publications in which the MEMS® have been used, or in which data from electronic monitoring figure in the content of the publication.

Updated: November 25th, 2002

Content

Peer-reviewed papers................................................................. 3

Review articles ........................................................................ 20

Published Lectures ............................................................... 24

Books .................................................................................... 25

Doctoral Dissertations ............................................................ 26

Book chapters ........................................................................ 26

Editorials, commentaries, special reports ......................... 31

Symposium articles and other unrefereed papers ............... 34

Letters .................................................................................. 38

Abstracts for papers or posters ............................................ 39

Contact us ............................................................................. 52
Peer-reviewed papers


P92-01. Rudd P, Ahmed S, Zachary V, Barton C, Bonduelle D. Compliance with medication timing: implications


“The introduction of the MEMS device is a breakthrough in the ability of pediatricians to differentiate between poor compliance and other pharmacokinetic and pharmacodynamic mechanisms leading to low serum concentrations and suboptimal clinical effects.”


First report of investigator fraud detected by MEMS® Monitoring.


INPHARMA summarized this paper as follows (4 Sept 93):

“Pill counts overestimate patient compliance say US researchers, and their continued use in clinical trials may be harmful. The belief that pill counts are reliable may mislead investigators, pharmaceutical industry sponsors and regulators, unless validating recording methods such as electronic monitoring are used to assess compliance. In particular, incorrect assessment of compliance may lead to ‘potentially dangerous approval of excessive dosages’.

“The researchers assessed medication taking behaviour among 19 patients with hypertension, using both pill counts and electronic monitoring. Patients took 1 pill per day for 63 weeks or more and pill taking was assessed at 1- to 4-week intervals. The study revealed that changes in medication-taking behaviour early in therapy may predict subsequent patient compliance rates and that prolonging drug action may compensate for some imperfect medication-taking behaviour.”


"Pill counts overestimated compliance, as revealed by the monitoring method. The times of actual consumption of doses by the patients often differed from that prescribed, predominantly in patients who were told to take the evening dose. Partial time compliance may have confounded the efficacy of the drugs. Electronic compliance monitoring appears to be particularly useful in chronopharmacological studies."


"Neither causal nor ambulatory day- or night-time readings detected a significant difference between morning and evening administration. However, self-measurement documented significantly greater blood pressure reductions for morning than for evening administration. The MEMS showed different compliance on the days of ambulatory monitoring (100% with both drug regimens) compared with the whole treatment period. The number of days with missed medication was thus significantly higher for the evening dosing regimen. The difference in self-measured blood pressure between the two regimens was lost if the days with missed medication were removed from the statistical analysis."


"Days without any dosing events were twice as often with the QD than the BID regimen. ... Episodes of 3 or more subsequent days without dosing events ... were also observed more often with the QD than the BID regimen. ... Doses were omitted more frequently on weekends than on any other day of the week ... (p<0.001). ... Evening doses were omitted about twice as often as ... morning doses [in] ... patients prescribed the BID regimen (p<0.001)."


"It is possible that all evaluations of efficacy and tolerance of migraine prophylactics reported so far have been unsoundly based [because of unrecognized variable compliance]."


... compliance assessed using the electronic Medication Event Monitoring System (MEMS) was better with the once-daily than with the twice-daily formulation; patients on the once-daily regimen performed better with respect to the total number of bottle openings, the number of openings per day, the timing of openings and the intervals between openings. The apparently superior compliance with the once-daily regimen appeared to be reflected in better efficacy; patients on the once-daily regimen experienced fewer angina attacks (a mean of 1.7 per 7 days, compared with 3.3 per 7 days for patients on the twice-daily regimen) and used fewer nitroglycerin tablets than those on the twice-daily regimen.


ABSTRACT: Intention-to-treat analysis, where the analyst essentially discards all information about compliance to assigned treatment, is the standard analytic approach to randomised clinical trials. When non-compliance is present, however, intention-to-treat analysis estimates only so called use-effectiveness, the average outcome difference attributable to prescribing, but not necessarily taking, the alternative treatments. Method effectivenss, the expected outcome difference among patients from some clinically relevant population if they did, in fact, adhere to their assigned regimen is an important issue, and trial results should also be analysed to estimate it. After discussing the usual estimators of treatment effect, including the intention-to-treat estimator, we emphasize that model-based analyses involving at least a model for the assignment mechanism (i.e., a model for how actual, not intended treatment is "assigned"), along with data on compliance and possibly on prognostically important covariates, can sometimes provide unbiased estimates of method-effectiveness despite non-compliance.


"The number of medications prescribed did not affect overall compliance because patients almost always took all tablets and capsules together if they took any medication."
"Assessment of medication adherence by provider, patient, and pill counts did not explain metabolic control as closely as assessment by MEMS."

"Various profiles were distinguished on the basis of the individual chronograms for the 501 patients able to be analysed in terms of compliance, and as a function of the deviations observed in relation to the treatment regimen prescribed. One hundred and two patients (20%) omitted more than 20% of the prescribed doses, either consecutive doses or scattered throughout the month of treatment; these patients were referred to as 'omitters'. The other patients were classified according to the scatter of openings in relation to the mean time of the dose: 10 'metronome' patients (2%), 126 'regular', patients (25%), 221 'irregular', patients (44%) and 42 'anarchic', patients (8%). Irregularities of dose times were more frequent on public holidays than on week days and in patients living in Paris or the Paris region."


"Results suggest supervised therapy and dispensing may be an effective strategy for improving AZT adherence, but only while provided."


"... the prescription of an antihypertensive medication with an action span greater than 24h would allow sufficient therapeutic coverage while respecting difference in patient's lifestyle."


"Many women were very enthusiastic about seeing the computer display of compliance. Patients often wanted to know their medication compliance rates over the previous 3-month period, and many were encouraged when they saw that they had been compliant. In addition, during refill appointments with MEMS readings, the patients would often explain why the medication dosages were..."
missed on certain days, which was helpful in gathering accurate dosing histories."


Abstract of paper follows:
“For population pharmacokinetic analysis of multiple oral doses one of the key issues is knowing as precisely as possible the dose inputs in order to fit a model to the input-output (dose-concentration) relationship. Recently developed electronic monitoring devices, placed on pill containers, permit precise records to be obtained over months, of the time/date opening of the container. Such records are reported to be the most reliable measurement of drug taking behavior for ambulatory patients. To investigate strategies for using and summarizing this new abundant information, a Markov chain process model was developed, that simulates compliance data from real data from electronically monitored patients, and data simulations and analyses were conducted. Results indicate that traditional population pharmacokinetic analysis methods that ignore actual dosing information tend to estimate biased clearance and volume and markedly overestimate random interindividual variability. The best dosing information summarization strategies consist of initial estimating population pharmacokinetic parameters, using no covariates and only a limited number of dose records, the latter chosen based on an a priori estimate of the half-life of the drug in the compartment of interest; then resummarizing the dose records using either population or individual posterior Bayes parameter estimates from the first population fit; and finally reestimating the population parameters using the newly summarized dose records. Such summarization strategies yield the same parameter estimates as using full dosing information records while reducing by at least 75% the CPU time needed for a population pharmacokinetic analysis.”


See also the detailed statistical report listed as E95-4.


“The children failed to comply with inhaled corticosteroid therapy, they misrepresented their steroid use, and they did so with the tacit approval of their parents. Failure to comply was linked with exacerbation of disease and the resultant need for administration of systemic steroids and hospitalization. Both the human toll and the financial burden may have been reduced by more conscientious adherence and reliable reporting. Inadequate control of asthma should alert the physician to the possibility of noncompliance, a behavior that is widespread and clearly not limited to those who are poorly informed or overtly uncooperative. A compelling need exists for objective means of assessing adherence because patient reports are unreliable and physicians do not judge compliance accurately. As clinicians, we must find ways that will encourage patients to comply with their therapy. It is evident that providing them with accurate information, though necessary, is not sufficient. Our responsibility extends beyond accurate diagnosis and appropriate recommendations. It is essential that we acknowledge and accept the responsibility for patient compliance, a direction more likely to result in better control of asthma than efforts to seek out more aggressive or
innovative therapies."


“The results suggest that the negative consequences of partial compliance for blood pressure control can be offset by choosing agents with a duration of action well beyond the dosing interval.”


P97-06. Roache JD, Stanley MA, Creson DR, Shah NN, Meisch RA. Alprazolam-reinforced medication use in


P98-05. Olivieri NF, Brittenham GM, McLaren CH, Templeton DM, Cameron RG, McClelland RA, Burt AD,

Use of electronic monitoring allowed the authors to make the following statement: "In our patients, differences in objectively determined rates of compliance ... could not account for the lack of effectiveness of deferiprone."


Note: Language: Portuguese, abstract in English.


"It is concluded that MEMS can measure adherence behaviour objectively, and so might be used to improve prescribing decisions, identify drug wastage, and improve carer support."


Bibliography of EM Publications.

Page 12


In discussion of the papers, of which this was one, from the Limburg Compliance Symposium, Sir David Cox commented: "It is excellent, however, that the first paper, by Drs. Urquhart and de Klerk, gives a fascinating account of measurement and definitional questions connected to compliance. The ideas and new methods outlined in that paper surely have major implications for design and statistical analysis." Stat Med 17: 387, 1998.


ABSTRACT: Nonadherence to treatment is a common problem in the clinical management of hypercholesterolemic patients. This study was carried out with the aim of monitoring the daily compliance to a 6-month course of lipid-lowering therapy, using a microelectronic device, the Medication Event Monitoring System (MEMS™), versus pill count. Forty men with primary hypercholesterolemia were prescribed fluvastatin 1 x 40 mg daily, provided in a MEMS package to record the date and time of each opening of the pillbox. Thirty-nine of 40 patients (98%) completed the study. Total cholesterol and LDL cholesterol levels decreased significantly (18% and 25%, p < 0.01) during the 6-month therapy period. A high mean rate of compliance was achieved by MEMS using the following three indexes-compliance to total prescribed dose (88.8% +/- 13.5%), compliance to prescribed days (82.4% +/- 19.5%), and compliance to prescribed time of day (81.86% +/- 19.5%)-and by pill count (93.4% +/- 9.5%). In addition, the MEMS provided some patterns of nonadherence to medication, undetectable by pill count alone, such as a drug holiday in 38% of cases, a drug omission for more than 7 consecutive days in 9% of cases, and, conversely, use of more than the one prescribed daily dose in 47% of cases. A significant correlation between the rate of compliance and the decrease in LDL cholesterol was observed only when the compliance was assessed by MEMS. The results indicate that MEMS is a useful tool for monitoring compliance in clinical practice and may possibly increase adherence to long-term lipid-lowering therapy.


"The findings in this paper illustrate how the compliance-correlates of observed therapeutic effectiveness can reveal the degree of forgiveness provided by the pharmaceutical in question, when prescribed at its recommended dose. Patients' actual dosing histories are almost invariably skewed downwards, towards varying degrees of under-dosing, relative to the prescribed regimen. It is important for good outcomes of treatment that the recommended regimen provide some degree of forgiveness for delayed and omitted doses. If, however, the degree of forgiveness seems excessive, as the Bachmann paper suggests may be the case for doxycycline treatment of C. trachomatis infections, then the results can be interpreted as support for the hypothesis that the recommended dose is set higher than necessary, and might beneficially be reduced. Indeed, the recommended doses of many pharmaceuticals have been discovered in the marketplace during the past two decades to be higher than necessary – see the papers by Cross et al. & by Heerdink et al. in Pharmacoepidemiology & Drug Safety 11: XX-446, and 447-453, 2002. In the editorial (E-99-5) that accompanies the Bachmann paper, the editorialist worries about potential biases, which may or may not be present, but which can, in any case, be resolved by treating the results in the Bachmann paper as “learning” (or hypothesis-generating) and then proceeding to test their validity in a suitably controlled “confirming” study, as described by Sheiner in his now-classic paper on the learn-confirm cycle in clinical investigation (R97-1)."


Key messages:
Non-adherence is a serious problem in the treatment of depression by general practitioners In this study a brief psychosocial intervention delivered by a nurse greatly improved adherence Clinical benefit was apparent only in patients with major depressive episodes on higher doses of drugs. Counseling should be targeted at patients with symptoms of at least moderate severity and combined with therapeutic drug doses


“Many early studies used pill counts as a reference standard, but electronic monitoring devices such as the Medication Event Monitoring System have replaced pill counts as the reference standard.”


“Conclusions: This study supports recent meta-analyses of SSRIs versus tricyclic antidepressants in finding no significant differences in crude indices of compliance between fluoxetine and dothiepin, despite marked differences in side effect profile and dose regimen. However, both a survival analysis and a new measure that takes account of prolonged periods of noncompliance distinguished between the treatments and was associated with improvement in both groups.”


P01-01. Valenti WM. Treatment adherence improves outcome and manages costs. The AIDS reader 2001 11(2) 77-80.


“Because MEMS is the most proximate and the most objective adherence measure—collecting data in real time as the pills are removed from the bottle and ingested—it is the backbone of CAS [Composite Adherence Score].”


"electronic monitoring is more sensitive than self-report for the detection of nonadherence and should be used in adherence intervention studies."


P02-03. Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS 2002 Jan 25;16(2):269-77


The authors demonstrated, using state-of-the art simulation techniques, that “the combination of electronic medication event monitoring with population PK methodologies has the potential to provide a robust method of capturing consistency and magnitude of individual concentration exposure. The identification of these factors will provide clinicians with the tools to more effectively tailor therapy and identify patients who are insufficiently and/or erratically exposure to pharmacotherapy”.

Review articles


Following is the article's conclusion (emphasis added):

"The literature is replete with reports of counselling patients to improve compliance. Unfortunately, most studies used inadequate methodology to assess compliance (i.e., performed before the 'gold standard' microelectronic monitoring methods were developed). Such studies have not documented the cost effectiveness of counselling programmes, apart from research settings, because of the time required for a professional counsellor. In clinical practice, few healthcare providers have the luxury of spending half an hour with a patient to discuss health beliefs or attempt to modify patient behaviour.

"The availability of microelectronic monitoring and feedback systems could change the cost equation. Computer-generated reports are instantly available and require less than 5 minutes for a complete review and discussion because most of the data are self-explanatory. For example, a patient who sees that their calendar shows no doses on weekends clearly comprehends the need for a better reminder plan for Saturday and Sunday doses. The frequent missing of bedtime doses demonstrates the need for an evening cue. Spending a few minutes to show patients how to tailor their medication regimens to fit into their schedules could greatly enhance overall compliance with medications. Currently available microelectronic monitoring systems allow clinicians to better understand patient dose-taking behaviours, and to utilise those data to help patients develop schedules that meet the individual's lifestyle.

"Microelectronic monitoring systems allow healthcare providers a better understanding of whether a medication (or dosage) has failed because of lack of efficacy, or failure of the patient to take the medication as prescribed. These issues are important in considering the cost of medical care as well as outcomes for individual patients. If available, dose frequency calendars and dose interval lists could be used as easily as results of blood tests. The data are not presented as a mark of a malingerer, but as evidence that the reason why less-than-expected efficacy is found is because the prescribed regimen is not being followed. Many people who take medications long term have neither any concept of how poorly they comply nor thoughts about how to enhance compliance by developing special tactics to remember dose times. It may be easier and more cost effective to monitor patients and use the electronically generated reports to help the physician and patient to see both the dose pattern and impact of partial compliance on outcome than to attempt behaviour modification for a population.

"In conclusion, the potential gains in improved self-care of individual patients, as well as clinical trial efficiency, are well worth the cost of monitoring units, particularly within the cost equation of managed care systems."


"Available data suggest that only a small subset (<20%) of hypertensive patients achieve goal blood pressure without full compliance. More than half of patients showing insufficient blood-pressure reduction exhibit suboptimal compliance, whether determined by pill count or bioassay. Only about one third of patients display the optimal combination of good blood-pressure control and satisfactory compliance."


ABSTRACT: Well-designed clinical trials maximize the information that can be obtained regarding the clinical pharmacology of a drug and, in turn, can streamline and enhance the drug development process. Until recently, little emphasis has been placed on integrating the role of variability in individual patterns of drug-taking into the drug development process.

With the use of electronic monitoring, the temporal relationship between an individual’s pattern of dosing and the prescribed regimen may be examined, and individual drug exposure may be estimated based on the actual history of dosing. As a result, accurate estimation of exposure-response relationships (or surrogate markers of response) can be obtained. Considerations in the design of clinical trials must therefore be expanded to include appropriate methods to measure compliance, sufficient frequency of monitoring to allow the time course of response to be mapped, and the use of statistically valid methods of data analysis.


“Compliance should be an integral part of study reports and publications, but it is frequently not discussed.”


1998.


Published Lectures

  Presidential Address to the 1991 Annual Meeting of the American Society for Clinical Pharmacology and
  Therapeutics.

  Inaugural professorial lecture, University of Limburg, Maastricht, NL, April 3, 1992.

  Science Chairman's Address, British Pharmaceutical Conference, 1993.

Lec94-1. Urquhart J. Compliance as a major determinant for the success of chronic drug treatment. Eur J
  Invited lecture at the 2nd European Conference on Pharmaceutical Sciences, Berlin, September 29,
  1994.

Lec95-1. Urquhart J. Correlates of variable patient compliance in drug trials: relevance in the new health care
  pp. 238-257. (Reprinted in citation B6, below)
  Boerhaave Lecture, University of Leiden, June 1, 1994.

Lec95-2. Urquhart J. The noncompliance tax: judging the costs of patient noncompliance and the economic
  value of intervening to improve compliance with crucial drug regimens. Pharmacoeconomics. Eds Breimer DD,
  Boerhaave Lecture, University of Leiden, April 20, 1995.

Lec99-1. Urquhart J. Measuring medication compliance – how can it be done? Proceedings of the International
  Working Conference on Outcomes Measurements in Pharmaceutical Care, Hillerod, Denmark, January 26-29,
  information on availability, contact m.schulz@abda.aponet.de)

Lec00-1. Urquhart J. Role of pharmacoepidemiology in adequate drug use. Symposium on the occasion of the
  retirement of Prof. Marc Bogaert, Heymans Institute of Pharmacology, Rijksuniversiteit Gent. Published in

Lec01-1. Urquhart J. The intelligent monitoring of compliance. 2nd Annual Al-Hammadi Lecture, Royal College
  of Physicians of Edinburgh, 41st Annual St Andrew's Day Festival Symposium, Edinburgh, December 6, 2001.
Books


Doctoral Dissertations


Book chapters


"The advantage of these devices [electronic medication monitors] is that actual times of dosing are recorded and can easily be recovered and displayed. A limitation of these devices is that the microprocessor records the opening and closing of the [package], rather than actual ingestion of the drug. ... Studies published thus far suggest that these limitations do not detract from the value of the information, and that these devices reflect true compliance reasonably accurately and quantitatively, ... The cost of the devices and the necessary ancillary equipment for recovering the data ... is modest compared with the cost of noncompliance and its consequences. A strong argument can be made for incorporating electronic monitoring into routine patient care, but this is not commonly done at this time." (p 1278)

Background: The explanatory power of measured antiretroviral drug exposure on virologic response in human immunodeficiency virus (HIV) infections is of great interest. Past studies showed the impact of aggregate intake of protease inhibitors (see, e.g., 1-3), but the impact of variations in dose-timing is still unclear. Substantial errors in dose timing occur in some patients who take all, or almost all, of the prescribed number of doses. Timing errors are incompletely characterized by the sometimes-used parameter ‘percentage of treatment days during which the correct number of doses were taken’. Here we look directly at the explanatory power of variations in interdose intervals. For reasons of taxonomic coherence (cf. 4), we use the term ‘patient compliance’ to mean ‘the extent to which the patient’s recorded dosing history corresponds to the prescribed regimen of drug administration’. This definition includes information on the timing of doses, and intervals between doses, as well as the amount of drug ingested.

Methods: From electronically compiled dosing histories (MEMS®, AARDEX Ltd) of naïve patients taking various protease inhibitors (5), we derived the usual parameters of patient compliance, i.e., percentage of prescribed doses taken, percentage of treatment days during which the correct number of doses were taken. We also derived a new parameter: Timing Error, which is related to the 3rd moment of the distribution of interdose intervals (6). We modeled viral load as a series of 4 ranges from <50 to >2000 copies/ml and examined analysis-derived probabilities for transitions between ranges. We compared the goodness of fit results from the analysis based on Timing Error vs other parameters of compliance, to predict rises or falls in viral load.

Results: Timing Errors were superior predictors of changes in viral load, compared to analyses based on the usual parameters of patient compliance. This result suggests that a few substantially prolonged inter-dose intervals have greater impact on viral load than do many marginally prolonged interdose intervals. Plots of Timing Error on the probabilities of change in viral load differ among protease inhibitors, suggesting that drugs of this class have differing degrees of forgiveness for longer interdose intervals.
Conclusion: Dose-timing data increase the explanatory power of data on patient compliance for antiretroviral treatment outcomes. The results suggest that avoidance of long interdose intervals should be a priority in efforts to improve patient compliance. We expect that the explanatory power of dose-timing data will vary from one drug and treatment situation to another. Further work is obviously needed.

References:

Editorials, commentaries, special reports


   The title reads: Compliance can be improved.


   "In our ongoing study of interventions to remediate adherence in patients with rheumatoid arthritis, ... out of 350 patients, 7% met our eligibility criteria for poor adherence when assessed by interview. With the electronic monitor, we identified 53% as eligible."


   Commentary on the presentation by William Insull at the Eur Atherosclerosis Soc meeting in Utrecht in June 1995. Insull is quoted as saying: "In short, if these medications fail to provide benefit to patients, it's not because the drugs don't work, it's most likely to be because the patient is noncompliant."

   Companion-piece to paper P39.


Symposium articles and other unrefered papers


S97-06. Hasford J. Problems with conventional analysis when non-compliance is prevalent. The Drug Holiday


"Low adherence of hypertensive patients to prescribed antihypertensive medications is a major cause of unsatisfactory blood pressure control. Several factors might have a negative influence on long-term adherence with treatment, for example a poor patient-doctor relationship and the presence of drug-induced side-effects. Various strategies are recommended in order to improve patient compliance, including educational programmes, self-measurement of blood pressure and monitoring of compliance. All methods may be helpful to encourage the patient to take the prescribed medication(s) regularly. It is also important to find a drug regimen which is at the same time simple, efficacious and well tolerated. Finally it should be pointed out that the motivation of the patient to follow the treatment requires the doctor to be equally motivated".


S00-03. Waeber B; Burnier M; Brunner HR. How to improve adherence with prescribed treatment in hypertensive patients? J Cardiovasc Pharmacol 2000;35 Suppl 3:S23-6

Letters


Abstracts for papers or posters


First description of the parameter, Therapeutic Coverage. Text follows:

"Partial compliance signifies sub-optimal dosing. Its consequences can be analyzed by jointly considering (a) the drug's pharmacodynamics and (b) data on dose timing from electronic compliance monitoring. Ideally, dose timing data would be input to a dynamic model of dose-dependent drug actions, projecting intervals of subtherapeutic drug action (ISDA). Duration and incidence of ISDA are pharmacodynamically logical correlates for analyzing dose-dependent bases for therapeutic failure, such as..."
"breakthrough" events (e.g., seizures during anti-epileptic treatment), not achieving an endpoint (e.g., reversing cardiac hypertrophy during hypertension treatment), etc. Data often are insufficient for dynamic modeling, but one can estimate duration and incidence of ISDA by noting when and for how long interdose intervals exceeded the drug's duration of action -- routinely measured, when feasible, for regimen optimization. Therapeutic Coverage (%TC) lumps computed ISDA as: 100 × [Duration of Treatment - ΣISDA] ÷ [Duration of Treatment]. %TC puts compliance data on a pharmacodynamic basis that "% of prescribed doses taken", which ignores dose timing, cannot.


Text of abstract follows:

Since the development in 1986-7 of reliable chemical markers (CM) and electronic monitoring (EM), the variability of dosing in ambulatory trials and practice has been shown to be far greater than indicated by older methods - pill counts, spot checks of drug levels, histories (1-4). CM and EM show predominant skew towards dose omission, with widely variable intervals between doses, though dosing in the day or two prior to scheduled visits is usually correct (1). The indelibly time/date-stamped record of EM has many uses.

EM is a primary source document of the patient's progress through a treatment protocol, sturdy enough to reveal instances of investigator fraud (5,6). Clinical correlates of variable dosing in nominally fixed-dose drug trials provide pragmatic information on dose-dependent drug action (7-9). Levy showed how dose-response parameters modulate consequences of variable dosing (10). "Compliance" can now be seen in PK/PD terms as the degree of correspondence between actual and prescribed time histories of dosing. EM data were used with a PK model to project the entire time history of drug concentrations in plasma during a multi-week study (11). If the drug's post-dose duration of action (Da) is known, Therapeutic Coverage (TC) can be computed thus: a segment, Si of the ith inter-dose interval, that exceeds Da, is considered a period of sub-optimal or absent drug action. TC is computed by summing the Sis, subtracting the sum from the EM period, and expressing the result as % of the EM period. Thus, 100% TC signifies no interdose interval >Da; when TC is <100%, the circadian timing of Si is informative. Long Si (drug "holidays") mark periods of long-lapsed efficacy, useful if prior knowledge specifies a critical Si, as with oral contraceptives (12); if not, efficacy correlates of Si help to develop such information. Si mark times of likely rebound effects, as with non-ISA beta blockers (13). Correlates of abruptly resumed dosing after long Si may reveal transient toxicity. Monte Carlo or bootstrap projections of dosing histories from trials may suggest pro-active steps to prevent hazardous dosing in market-sized populations.

REFERENCES


A95-4. Oakley D, Canamar R, Potter L. Measuring oral contraceptive pill use. Poster presented at meetings of


A96-14. Waeber B. What can be learned from monitoring treatment compliance in antihypertensive drug trials?


Abstracts A101-4 come from the symposium, “Methods for Measuring Compliance: Influence on Recommended Dose”, at the VI World Congress of Clinical Pharmacology & Therapeutics, Buenos Aires, August 7, 1996.


A96-27. Magometschnigg D. Targeting the right of patients using hypertension as an example — the beneficiaries, the contributors. Workshop Compendium, Drug Information Association Workshop on Drug Compliance Issues in Clinical Trials & Patient Care. Paris, Sept 30, Oct 1, 1996. (3 pp)

Bibliography of EM Publications.  
Page 48


A01-6. Mellors MP, Erlen JA, Sereika SM, Ptanchcinski RJ. Personality traits and adherence to antiretroviral therapy. Program and abstracts of the 14th annual conference of the association of nurses in AIDS Care; Nov. 11-14, 2001, Minneapolis MI. Abstract Session III.
Contact us

**AARDEX Europe**
Barbara Wittwer
Untermüli 6
P.O. Box 2026
6302 Zug Switzerland
tel +41-41-76 801 01
fax +41-41-76 322 35
internet: info@aardex.ch

**AARDEX USA: APREX, a division of AARDEX**
Marilyn Wells
2849-B Whipple Road
Union City, California 94587
USA
tel +1-800-524-6833 or 510-476-1940
fax: 510-476-1946
internet: marilyn@aardex.ch

The AARDEX bibliography is maintained by prof. J. Urquhart and dr. E. de Klerk.